糖尿病心肌病治疗中GLP-1心血管系统保护效应的研究进展  

Progress in Cardiovascular Protective Effect of GLP-1 in Treatment of Diabetic Cardiomyopathy

作　　者：夏文静 黄问银 唐新虎 谷翔 XIA Wenjing;HUANG Wenying;TANG Xinhu;GU Xiang(Department of Cardiovascular Medicine,Jiujiang University Affiliated Hospital,Jiujiang 332000,China)

机构地区：[1]九江学院附属医院心血管内科,江西九江332000

出　　处：《医学综述》2022年第9期1758-1762,共5页Medical Recapitulate

基　　金：江西省青年科学基金(20171BAB215029);国家自然科学基金(81960167)。

摘　　要：糖尿病心肌病作为糖尿病常见的并发症,发病率高、对患者生活质量及预后影响大,是糖尿病临床治疗的重点和难点。源自肠道细胞的新型降糖药物胰高血糖素样肽-1(GLP-1)可与体内广泛分布的特异性受体结合,通过多种机制调控血糖;并且干预心血管疾病危险因素,调节心肌细胞凋亡、自噬,改善血管内皮细胞功能和心肌供血。同时,GLP-1还可降低心肌梗死、心力衰竭、心源性死亡等心血管事件的发生风险,发挥除降糖效应外的心血管系统保护效应,有望成为糖尿病心肌病临床治疗的新方法。As a common complication of diabetes,diabetic cardiomyopathy has a high incidence,which affects the quality of life and prognosis of diabetic patients,and is the emphasis and difficulty in clinical treatment of diabetes.The new glucose-lowering drug glucagon-like peptide-1(GLP-1),secreted by intestinal cells,interacts with its specific receptors which widely distributes in the body and regulates blood sugar through a variety of mechanisms.GLP-1 intervenes the major risk factors of cardiovascular diseases,regulates apoptosis and autophagy of myocardial cells,improves the function of endothelial cells and myocardial blood supply.Besides,GLP-1 can also reduce the risk of cardiovascular events including myocardial infarction,heart failure and cardiovascular death,thus playing a protective effect to cardiovascular system,and is expected to provide new clinical treatments to diabetic cardiomyopathy.

关 键 词：糖尿病心肌病 胰高血糖素样肽-1 心血管疾病 

分 类 号：R541.9[医药卫生—心血管疾病]